BiotechTube

Eltrombopag + IVIG infusion

Phase 3Completed
1 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Immune Thrombocytopenic Purpura

Conditions

Immune Thrombocytopenic Purpura

Trial Timeline

Oct 1, 2012 → Aug 1, 2019

NCT ID
NCT01621204

About Eltrombopag + IVIG infusion

Eltrombopag + IVIG infusion is a phase 3 stage product being developed by Novartis for Immune Thrombocytopenic Purpura. The current trial status is completed. This product is registered under clinical trial identifier NCT01621204. Target conditions include Immune Thrombocytopenic Purpura.

What happened to similar drugs?

7 of 20 similar drugs in Immune Thrombocytopenic Purpura were approved

Approved (7) Terminated (2) Active (13)
✅Lopinavir 400 mg/ritonavir 100 mg + EfavirenzGilead SciencesApproved
✅IgPro10CSLApproved
✅Subcutaneous Immune Globulin (Human) (Hizentra)CSLApproved
✅Methylprednisolone + PrednisoloneBiogenApproved
✅Flebogamma 5% DIFGrifolsApproved
✅Asceniv™ADMA BiologicsApproved
✅BivigamADMA BiologicsApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT01621204Phase 3Completed

Competing Products

20 competing products in Immune Thrombocytopenic Purpura

See all competitors
ProductCompanyStageHype Score
Pirtobrutinib + PlaceboEli LillyPhase 1/2
39
Anti-(integrin beta-3) human monoclonal antibodyRallybioPhase 2
17
SatralizumabChugai PharmaceuticalPhase 3
47
Placebo + LusutrombopagShionogiPhase 2
27
LusutrombopagShionogiPhase 2
27
RomiplostimKyowa KirinPhase 1/2
32
AMG 531Kyowa KirinPhase 2/3
38
Romiplostim + PlaceboKyowa KirinPhase 3
40
Romiplostim (AMG-531)Kyowa KirinPhase 2
35
Romiplostim and danazolKyowa KirinPhase 2
31
Hetrombopag OlamineJiangsu Hengrui MedicinePhase 1
29
SHR0302 quick release tablets + SHR0302 sustained-release tabletsJiangsu Hengrui MedicinePhase 1
29
Hetrombopag + PlaceboJiangsu Hengrui MedicinePhase 3
40
HR19042 Capsule, Tarpeyo®, Budenofalk®Jiangsu Hengrui MedicinePhase 1
29
HR19042 CapsulesJiangsu Hengrui MedicinePhase 2
35
HerombopagJiangsu Hengrui MedicinePhase 3
36
Zostavax®MerckPre-clinical
18
Raltegravir + AtazanavirMerckPre-clinical
26
ZostavaxMerckPre-clinical
26
MK-8723 + Matching PlaceboMerckPhase 1
29